In brief
Big pharma companies are sourcing new drugs from Chinese biotech firms, according to Goldman.
Approximately $440 billion worth of drugs will lose patent protection through 2032, according to Richter.
Could Summit's Keytruda battle prove that China-sourced drugs work in the West?
Read the original Goldman Sachs story: China biotech is where big pharma is shopping now, by Darryn Pollock: nl.beincrypto.com